Posted by Michael Wonder on 23 Jun 2022
Novartis receives European Commission approval for Tabrecta for the treatment of METex14 skipping advanced non-small cell lung cancer
22 June 2022 - Approval based on the Phase II GEOMETRY mono-1 trial, which showed an overall response rate of 51.6% in a cohort evaluating primarily second-line patients and 44% in all previously-treated patients with advanced NSCLC harbouring alterations leading to METex14 skipping.
Novartis announced today that the European Commission approved Tabrecta (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
